- Home
- BCDA vs ATPC Comparison
BCDA vs ATPC Comparison
Compare BCDA & ATPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ATPC
- Stock Information
- Founded
- BCDA N/A
- ATPC 2016
- Country
- BCDA United States
- ATPC Malaysia
- Employees
- BCDA N/A
- ATPC N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ATPC Medical/Nursing Services
- Sector
- BCDA Health Care
- ATPC Health Care
- Exchange
- BCDA Nasdaq
- ATPC Nasdaq
- Market Cap
- BCDA 10.1M
- ATPC 68.0M
- IPO Year
- BCDA N/A
- ATPC N/A
- Fundamental
- Price
- BCDA $2.39
- ATPC $1.47
- Analyst Decision
- BCDA Strong Buy
- ATPC
- Analyst Count
- BCDA 1
- ATPC 0
- Target Price
- BCDA $25.00
- ATPC N/A
- AVG Volume (30 Days)
- BCDA 230.7K
- ATPC 55.8K
- Earning Date
- BCDA 08-12-2025
- ATPC 08-13-2025
- Dividend Yield
- BCDA N/A
- ATPC N/A
- EPS Growth
- BCDA N/A
- ATPC N/A
- EPS
- BCDA N/A
- ATPC N/A
- Revenue
- BCDA $3,000.00
- ATPC $1,293,141.00
- Revenue This Year
- BCDA N/A
- ATPC N/A
- Revenue Next Year
- BCDA N/A
- ATPC N/A
- P/E Ratio
- BCDA N/A
- ATPC N/A
- Revenue Growth
- BCDA N/A
- ATPC N/A
- 52 Week Low
- BCDA $1.63
- ATPC $0.90
- 52 Week High
- BCDA $4.66
- ATPC $6.80
- Technical
- Relative Strength Index (RSI)
- BCDA 58.67
- ATPC 45.37
- Support Level
- BCDA $1.98
- ATPC $1.37
- Resistance Level
- BCDA $2.45
- ATPC $1.47
- Average True Range (ATR)
- BCDA 0.17
- ATPC 0.09
- MACD
- BCDA 0.04
- ATPC 0.02
- Stochastic Oscillator
- BCDA 88.00
- ATPC 47.48
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ATPC Agape ATP Corporation
Agape ATP Corp through its subsidiaries is engaged in providing health and wellness products and health solution advisory services. The principal activities of the company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs. Its segments include: Skin care, health and wellness segment includes the provision of health and wellness products and health solution advisory services; and Green energy segment includes providing renewable energy products, technical solutions, installations and maintenance services. It derives maximum revenue from Skin care, health and wellness segment.